Latest
-
How Cytonics' Developed a Revolutionary Treatment for Osteoarthritis, Solving a $240B Problem
Sponsored Sponsored Content by Cytonics
Sponsored -
Weed Legalization in Florida Gains Ground: This Week in Cannabis Investing
Enough signatures have been gathered to take recreational weed legalization efforts in Florida to the next step.
-
Starting Today, Hearing Aids May be Sold Over the Counter
Healthy Living on a Budget The White House estimates people will save nearly $3,000 by not having to get them through a medical professional.
Healthy Living on a Budget -
Medicare to Consider Lowering Part B Premiums
Medicare Beneficiaries could see a reduced Part B premium after Biogen announced it would slash the price of its expensive, and controversial, new Alzheimer's treatment, Aduhelm.
Medicare -
Medicare Part B Premium Jumps Dramatically for 2022
Medicare Rising health care costs and the approval of Aduhelm, a new expensive Alzheimer's drug, were partly to blame for increases in the Part B premium and deductible.
Medicare -
8 Biotech Stocks With Major Catalysts on the Horizon
investing Biotech stocks frequently make big moves on a single trial result or FDA ruling. These 8 drugmakers are worth watching amid important events on deck this summer.
investing -
Save the Date: 11 Biotech Stocks to Put on Your Radar
stocks Here are 11 biotech stocks and pharmaceutical companies to watch over the next few months.
stocks -
Medicare Doesn't Cover Hearing Aids but Retirees Have Options
Medicare Medicare and most health insurance don't cover hearing aids, but alternatives including over-the-counter devices can be less expensive.
Medicare -
10 Blockbuster Drugs of the Future
investing The pharmaceutical industry occasionally hits a home run by creating a drug that generates sales in excess of $1 billion per year – the watermark for what constitutes a so-called “blockbuster.” These heavy-hitters are a rarity relative to the number of drugs that begin development but never really go anywhere.
investing
